Moderna Stock: Speculations Regarding the Company’s Stock
Moderna stock boosted after it announced its vaccine and after this, it was expected that the company’s stock would perform well. However, things did not go as smoothly as expected and the stock fluctuated a lot. The company’s stock faced ups and downs lately and this has made the decision of investing in Moderna stock quite speculative. Moderna’s vaccine got approved by the Food and Drug Administration (FDA). It was developed and formulated using the messenger RNA (mRNA) technology and in this matter, the vaccine shares its similarity with the vaccine that Pfizer developed with its partner BioNTech and got it approved. Moderna Inc. (NASDAQ: MRNA) Moderna has claimed that its vaccine is 94.1% effective against the infection of the novel coronavirus. The vaccine has got approval and authorization in various countries around the world (more than 30). The company is making more and more doses of the vaccine as per the requirement of the same. 1.4 billion doses of this vaccine are expected in this year 2021 and could be more depending upon the demand of the vaccine. The final quarter revenue of Moderna has come out to be $571 million (in 2019, the fourth-quarter revenue was $14 million). The total annual revenue for the year 2020 was $803 million. Moderna’s Latest Report on Statistics 52 Week Range: $19.31 - $189.26 Average Volume: 18,759,237 Market Capital: $52.458B Forward Dividend and Yield: N/A (N/A) When is the Right Time to Invest in Moderna Stock? Moderna has not had a very…